Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

NCT ID: NCT02709655

Last Updated: 2022-09-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

683 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-18

Study Completion Date

2022-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vortioxetine 10 mg/day

Group Type EXPERIMENTAL

Vortioxetine 10 mg/day

Intervention Type DRUG

10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Vortioxetine 20 mg/day

Group Type EXPERIMENTAL

Vortioxetine 20 mg/day

Intervention Type DRUG

20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Fluoxetine 20 mg/day,

A decision has been taken to stop recruitment into this treatment arm.

Group Type ACTIVE_COMPARATOR

Fluoxetine 20mg/day

Intervention Type DRUG

20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Encapsulated tablet, orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vortioxetine 10 mg/day

10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention Type DRUG

Vortioxetine 20 mg/day

20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention Type DRUG

Fluoxetine 20mg/day

20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

Intervention Type DRUG

Placebo

Encapsulated tablet, orally

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brintellix ® Lu AA21004 Brintellix ® Lu AA21004

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™).
2. The participant has a CDRS-R total score ≥45 at the Screening Visit and the Baseline.
3. The participant has a CGI-S score ≥4 at the Screening Visit and the Baseline.
4. The participant is a boy or girl, aged ≥7 and \<12 years at Screening Visit
5. The participant has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.

Exclusion Criteria

1. The participant has participated in a clinical study \<30 days prior to the Screening Visit.
2. The participant has previously participated in a study with vortioxetine.
Minimum Eligible Age

7 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Takeda

INDUSTRY

Sponsor Role collaborator

H. Lundbeck A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Email contact via Lundbeck A/S

Role: STUDY_DIRECTOR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Woodland International Research Group

Little Rock, Arkansas, United States

Site Status

Sun Valley Research Center

Imperial, California, United States

Site Status

Synergy Clinical Research Center

Lemon Grove, California, United States

Site Status

Alliance for Wellness dba Alliance for Research

Long Beach, California, United States

Site Status

NRC Research Institute

Orange, California, United States

Site Status

Asclepes Research Center

Panorama City, California, United States

Site Status

Children's National Medical Center Merge

Washington D.C., District of Columbia, United States

Site Status

Sarkis Clinical Trials

Gainesville, Florida, United States

Site Status

Medical Research Group of Central Florida

Orange City, Florida, United States

Site Status

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Site Status

Northwest Behavioral Research Center

Marietta, Georgia, United States

Site Status

American Medical Research, Inc.

Chicago, Illinois, United States

Site Status

AMR- Baber Research, Inc.

Naperville, Illinois, United States

Site Status

AMR Conventions Research

Warrenville, Illinois, United States

Site Status

Kansas University School of Medicine-Wichita

Wichita, Kansas, United States

Site Status

Lake Charles Clinical Trials

Lake Charles, Louisiana, United States

Site Status

Kennedy Krieger Institute

Baltimore, Maryland, United States

Site Status

St. Charles Psychiatric Associates - Midwest Research Group

Saint Charles, Missouri, United States

Site Status

Millennium Psychiatric Associates, LLC

St Louis, Missouri, United States

Site Status

Princeton Medical Institute

Princeton, New Jersey, United States

Site Status

Manhattan Behavioral Medicine

New York, New York, United States

Site Status

Finger Lakes Clinical Research

Rochester, New York, United States

Site Status

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status

University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry

Cleveland, Ohio, United States

Site Status

North Star Medical Research, LLC

Middleburg Heights, Ohio, United States

Site Status

IPS Research Company

Oklahoma City, Oklahoma, United States

Site Status

Paradigm Research Professionals, LLC

Oklahoma City, Oklahoma, United States

Site Status

Research Strategies Of Memphis, Llc

Memphis, Tennessee, United States

Site Status

BioBehavioral Research of Austin

Austin, Texas, United States

Site Status

AIM Trials, LLC

Plano, Texas, United States

Site Status

Research Across America

Plano, Texas, United States

Site Status

Clinical Trials of Texas, Inc.

San Antonio, Texas, United States

Site Status

Westside Medical

Clinton, Utah, United States

Site Status

Aspen Clinical Research, LLC

Orem, Utah, United States

Site Status

MHAT Targovishte AD

Targovisthe, , Bulgaria

Site Status

Diagnostic Consultative Center Mladost-M Varna OOD

Varna, , Bulgaria

Site Status

Paediatric Sleep Research Inc.

Toronto, Ontario, Canada

Site Status

E.S.E. Hospital Mental de Antioquia HOMO

Bello, Antioquia, Colombia

Site Status

Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS.

Barranquilla, Atlántico, Colombia

Site Status

Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS

Bogotá, DC, Colombia

Site Status

Psynapsis Salud Mental S.A.

Pereira, Risaralda Department, Colombia

Site Status

Marienthali Kliinik

Tallinn, , Estonia

Site Status

Cabinet Psyche

Douai, Nord, France

Site Status

Centre Medical Ambroise Pare

Élancourt, , France

Site Status

CHU de Nantes - Hopital Hotel Dieu

Nantes, , France

Site Status

Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri

Mainz, , Germany

Site Status

Vadaskert Alapitvany

Budapest, , Hungary

Site Status

Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza

Gyula, , Hungary

Site Status

Shalvata Mental Health Center

Hod HaSharon, , Israel

Site Status

Ramat Chen - Mental Health Clinic

Tel Aviv, , Israel

Site Status

The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital

Tel Litwinsky, , Israel

Site Status

Scientific Institute Fondazione Stella Maris

Calambrone Pisa, Pisa, Italy

Site Status

Sciaf Ulss 16 Padova

Padua, Regione Veneto, Italy

Site Status

University Federico II Of Naples

Napoli, , Italy

Site Status

Linda Keruze's Psychiatric Center, LLC

Liepāja, , Latvia

Site Status

Children Hospilal -Gailezers

Riga, , Latvia

Site Status

Centro Investigacion Medico Biologica Y Terapia Avanzada

Guadalajara, Jalisco, Mexico

Site Status

Clinica Cemelli

Guadalajara, Jalisco, Mexico

Site Status

Roberto Zepeda Sanchez

Guadalajara, Jalisco, Mexico

Site Status

Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)

Mexico City, Mexico City, Mexico

Site Status

CRI Centro Regiomontano de Investigacion SC

Monterrey, Nuevo León, Mexico

Site Status

Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C

Culiacan de Rosales, Sinaloa, Mexico

Site Status

B & B Investigaciones Medicas, SC

Mazatlán, Sinaloa, Mexico

Site Status

ICARO Investigaciones en Medicina S.A. de C.V.

Chihuahua City, , Mexico

Site Status

BIND Investigaciones S.C

San Luis Potosí City, , Mexico

Site Status

Prywatne Gabinety Lekarskie Promedicus

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Centrum Badan Klinicznych PI-House Sp. z o.o.

Gdansk, , Poland

Site Status

Przychodnia Syntonia Poradnia Zdrowia Psychicznego

Kielce, , Poland

Site Status

Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny

Lublin, , Poland

Site Status

Filip Rybakowski Specjalistyczna Praktyka Lekarska

Poznan, , Poland

Site Status

Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu

Wałbrzych, , Poland

Site Status

Medicorehabilitation Research Center Phoenix

Rostov-on-Don, Rostov State, Russia

Site Status

Stavropol Region Psychiatric Hospital No.2

Stavropol, Stavropol Kray, Russia

Site Status

Arkhangelsk Regional Clinical Mental Hospital

Arkhangelsk, , Russia

Site Status

GUZ Engels Psychiatric Hospital

Engel's, , Russia

Site Status

State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ...

Krasnodar, , Russia

Site Status

LLC City Neurological Center Sibneuromed

Novosibirsk, , Russia

Site Status

Rostov State Medical University of the Minzdravsotsrazvitiya of Russia

Rostov-on-Don, , Russia

Site Status

City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov

Saint Petersburg, , Russia

Site Status

Saratov State Medical University

Saratov, , Russia

Site Status

Guz Saratov Regional Psychiatric Hospital St. Sofii

Saratov, , Russia

Site Status

Nebbiolo LLC

Tomsk, , Russia

Site Status

Yaroslavl Regional Clinical Psychiatry Hospital

Yaroslavl, , Russia

Site Status

State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi...

Yekaterinburg, , Russia

Site Status

Child and Adolescent Neurology and Psychiatry Clinic

Belgrade, , Serbia

Site Status

Institute of Mental Health

Belgrade, , Serbia

Site Status

University Clinical Center Kragujevac

Kragujevac, , Serbia

Site Status

Clinical Center of Vojvodina - Clinic of Psychiatry

Novi Sad, , Serbia

Site Status

Daily Hospital for Children and Adolescents

Pantelej-Nis, , Serbia

Site Status

Cape Trial Centre

Bellville, Cape Town, South Africa

Site Status

Tara Hospital

Sandhurst, Gauteng, South Africa

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Hospital Universitario Fundacion Alcorcon

Alcorcón, Madrid, Spain

Site Status

Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo

Torremolinos, Malaga, Spain

Site Status

Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro...

Kyiv, , Ukraine

Site Status

Odessa Regional Medical Centre of Mental Health

Odesa, , Ukraine

Site Status

Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U...

Poltava, , Ukraine

Site Status

Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers...

Ternopil, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Canada Colombia Estonia France Germany Hungary Israel Italy Latvia Mexico Poland Russia Serbia South Africa South Korea Spain Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Huss M, Findling RL, DelBello MP, Necking O, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study. JAACAP Open. 2024 Nov 22;3(3):736-748. doi: 10.1016/j.jaacop.2024.11.002. eCollection 2025 Sep.

Reference Type DERIVED
PMID: 40922774 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-005353-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

12709A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.